Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people begin to notice weight loss on Wegovy within the first four to eight weeks of treatment, though meaningful changes in body weight typically build over three to six months as the dose increases toward the therapeutic range. Wegovy (semaglutide) is a prescription-only medicine, and how quickly you respond depends on where you are in the titration schedule, your starting weight, your diet, and your level of physical activity. No two people follow exactly the same timeline, and a prescriber is best placed to help you read your own progress. That said, understanding what the clinical evidence shows — and what it doesn't — makes it easier to approach the early weeks with realistic expectations rather than frustration.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When someone starts Wegovy, the question they're actually navigating isn't purely scientific. It's whether to trust a slow process in a culture that expects fast results. The clinical trial that underpins Wegovy's UK licence (the STEP 1 study, published in the New England Journal of Medicine) followed 1,961 adults for 68 weeks and found an average body weight reduction of around 15% at the 2.4mg maintenance dose. That average was built over more than a year. Not a fortnight.
The practical decision most people face in weeks two through six is whether slower-than-expected early progress means the medicine isn't working. In the vast majority of cases, it does not. At 0.25mg (the starting dose) semaglutide is calibrated to help your body adjust, not to produce maximum weight loss. The appetite-suppressing effect is real at this stage, but the full pharmacological impact comes later, as the dose climbs.
If you find yourself weighing in daily and feeling despondent, it helps to shift the metric. Notice instead whether portions feel smaller naturally, whether you're stopping eating sooner, whether the urge to snack has quietened. Those changes are the medicine doing exactly what it's supposed to do, and they precede the scale catching up. If you want a fuller picture of how long before you see weight loss on Wegovy, including what the evidence says about the early weeks of treatment, that page walks through the timeline in detail.
The Wegovy titration pathway runs 0.25mg, then 0.5mg, 1.0mg, 1.7mg, and finally 2.4mg, with each step spaced roughly four weeks apart. That means most people reach the standard maintenance dose somewhere around month five. The NHS semaglutide guidance describes the schedule clearly and is worth reading alongside your Patient Information Leaflet for the full picture.
In practice, the pattern tends to look something like this. The first few weeks often bring GI side effects (nausea, loose stools, reduced appetite) more than visible weight change. Between weeks four and twelve, many people lose between 2% and 5% of their body weight, sometimes more. From month three onward, as doses increase, weight loss tends to accelerate. By month six most people who are going to respond well have lost somewhere between 5% and 10% of their starting weight, often more. The final phase, from around month nine to the end of the 68-week trial period, is where a larger portion of the 15% average accumulates.
One thing worth saying plainly: the 7.2mg dose approved by the MHRA in early 2026 pushes the ceiling higher still, with trials reporting around 20.7% average weight loss over 72 weeks. Your prescriber decides which dose is right for you based on your response and tolerance, not on a fixed target. For more on how the overall mechanism plays out in practice, our overview of Wegovy as a treatment covers the pharmacology in plain terms.
A common misconception worth letting go of gently: if the number on the scale hasn't shifted after two weeks, it doesn't mean nothing is happening. Body weight fluctuates daily by one to three kilograms depending on hydration, salt intake, the time of day you weigh, and your menstrual cycle if that applies to you. A single morning weigh-in after a salty dinner the night before tells you very little. Weekly weigh-ins, at the same time, on the same scales, give a more honest picture. Monthly trends are more honest still.
Some people also gain water weight in the very first week as the body adjusts to dietary changes alongside starting the medicine. This resolves quickly and is not fat gain. Equally, muscle is denser than fat: if you've added any strength activity alongside treatment, the scale may move more slowly than your clothes size suggests. The numbers that matter most over a six-month period are the trend line, not any single data point.
If you'd like a clearer sense of how long before weight loss on Wegovy typically begins, that page goes into the clinical detail behind the early weeks. For a closer look at when you actually notice weight loss on Wegovy, including the difference between what the scale shows and what you feel day to day, our dedicated page breaks that down stage by stage. And if you're thinking about what a typical trajectory looks like end to end, our page on how long before you lose weight on Wegovy provides context drawn from the trial data, including a breakdown of what to expect at each stage of dose escalation. If you'd also like to see how results tend to look in real people over time, the page on Wegovy weight loss before and after pulls together representative outcomes from the clinical evidence.
There are situations where slow progress does warrant a clinical conversation rather than simply waiting. If you have been at the 2.4mg maintenance dose for six months and have lost less than 5% of your starting weight, NICE guidance suggests that continuing treatment should be reviewed. That threshold exists to make sure the balance of benefits and side effects is right for you personally, not as a judgement on effort.
Side effects can also affect how well the treatment works in practice. Persistent nausea that makes it hard to eat well, or GI symptoms that lead to poor hydration, can blunt progress and also need clinical attention in their own right. Your prescriber can adjust timing, discuss anti-nausea strategies, or consider whether the dose increase schedule needs to slow down.
Wegovy is a prescription-only medicine and that matters practically: access to clinical oversight is part of how it's supposed to work, not an optional extra. If you're considering starting treatment and want to understand what timescale is realistic for your situation, speaking with a prescriber who can look at your full picture is the most useful step. At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, and aftercare is available seven days a week if questions come up between doses. For a broader look at what weight-loss treatment involves, our weight loss treatments overview is a good starting point, or you can speak to our prescribers directly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.